Skip to main content
. 2022 Jun 11;20:2986–3003. doi: 10.1016/j.csbj.2022.06.015

Fig. 2.

Fig. 2

Overview of human β-globin locus and ex vivo gene therapy for the treatment of SCD and TDT. A) Schematic representation of human β-globin locus and LCR; B) Erythroid-specific expression of β-like globin transgenes using lentiviral vectors; C) Schematic representation of lentiviral gene addition therapy and HBB mutation-independent therapeutic approaches for the treatment of SCD and TDT.